Seminars are hosted each year by a different PIC/S Participating Authority. Each Seminar focuses on a particular aspect of GMP with the aim of providing training and harmonisation in the field covered. Annual PIC/S training Seminars are open to Inspectors from PIC/S Participating Authorities and other interested Medicine Regulatory Authorities. Seminars are not open to Industry

2020 Seminar on "How to be a good GMP Inspector in 2020"   

Thailand's Food and Drug Administration (Thai FDA) is hosting the 2020 PIC/S Seminar on "How to be a good GMP Inspector in 2020" in Bangkok (Thailand) from 18-20 November 2020.

More information will shortly be available.

Key Features of Seminars

PIC/S Seminars last for 2.5 days and are attended on average by more than 100 Inspectors from all over the world. All participants must pay for their own costs (registration fee & accommodation).

Seminars are not profit-oriented. They are organised by Regulatory Authorities for Regulatory Authorities in line with the PIC/S Aide-Memoire on Organisation of Seminars. Industry cannot attend as such PIC/S Seminars except as invited speakers. Most presentations are given by active Inspectors while only a few are given by speakers from other fora (university, organisations, industry, etc.). 

The outcome of Seminars usually results in the formation of a Working Group to develop a draft Guidance or Recommendation. For example, the 2004 Seminar on Active Pharmaceutical Ingredients (APIs) resulted in the preparation and the issuing of the PIC/S Aide-Memoire on the inspection of APIs.

Past Seminars

PIC/S Participating Authorities have hosted Seminars since 1971. The following list offers an overview of Seminar topics and hosts over the years.




2019 Quality Assurance of Sterile Medicinal Products - Annex 1 Toyama | Japan
2018 Management of Risk through the Product Life-Cycle Chicago | USA
2017 Quality Control Laboratories: How to Inspect Taipei | Chinese Taipei
2016 Inspectorates of the Future Manchester | UK
2015  Biopharmaceuticals (Biotechnology and Biologicals): How to Inspect Nusa Dua | Indonesia
2014 Dedicated Facilities: Yes or No Paris | France
2013 Global Supply Chains and GMP Compliance Ottawa | Canada
2012 Qualification and Validation: Today and Tomorrow Kiev | Ukraine
2011 Good Pharmaceutical Inspection Practices Cape Town | South Africa
2010 GMP Inspection of Manufacturers of Traditional / Herbal Medicinal Products Kuala Lumpur | Malaysia
2009 Inspection of Aseptic & Sterile Manufacturing from APIs to finished dosage forms Uppsala | Sweden
2008 Good Distribution Practices Krakow | Poland
2007 The Inspection of the Manufacture of Solid Dosage Forms Singapore | Singapore
2006 Quality Risk Management and related ICH topics  Düsseldorf | Germany
2005 Primary packaging material, labelling and the prevention of mix-ups (including counterfeit packaging and labelling) Bucharest | Romania
2004 The Inspection of Manufacturers of Active Pharmaceutical Ingredients Barcelona | Spain
2003 The Inspection of Quality Control Laboratories Bratislava | Slovak Republic
2002 The Interface Between Good Clinical Practice (GCP) and GMP in the Manufacture and Audit of Clinical Trial Products Montebello, QC | Canada
2001 Utilities Used by the Manufacturer of Pharmaceuticals Prague | Czech Republic
2000 The Inspection of Products derived from Biotechnologies Colmar | France
1999 Non-Technical Aspects of Inspection Oxford | United Kingdom
1998 Quality Systems for Pharmaceutical Inspectorates Zeist | Netherlands
1997 Manufacture and Inspection of Active Pharmaceutical Ingredients Naantali | Finland
1996 GMP Standards for Active Pharmaceutical Ingredients Canberra | Australia
1996 Inspection of Computer Systems Sydney | Australia
1995 Inspecting the Manufacture of Sterile Products - Current and Future Trends Hveragerði | Iceland
1994 Qualification and Validation in Pharmaceutical Manufacture Dublin | Ireland
1993 The Role of Inspection and Testing in relation to the Marketing Authorisation Louvain-la-Neuve | Belgium
1992 New Aspects of Products Derived from Biotechnology Montecatini Terme | Italy
1991 Audit - Pharmaceutical Inspection Felsötárkány | Hungary
1990 Blood and Blood Products Hillerød | Denmark
1989 Contamination Risks in the Manufacture of Parenterals Baden | Austria
1988 Water for Pharmaceutical Purposes Jongny | Switzerland
1987 The Business of Pharmaceutical Inspection Cambridge | United Kingdom
1986 Plastics and their Pharmaceutical Applications Sigtuna | Sweden
1985 Premises for Pharmaceutical Manufacture Oslo | Norway
1984 Requirements of Good Manufacturing Practice and Quality Control in the Production of Biological Products Frankfurt a/Main | Germany
1983 Safety Aspects of the Packaging of Pharmaceutical Products Lisbon | Portugal
1982 Validation Dublin | Ireland
1981 Application of GMP Rules in the Control Laboratory Budapest | Hungary
1980 Good manufacturing Practice in the Manufacture of Active Ingredients Liestal/Basel | Switzerland
1980 Inspection in Tablet Manufacture Copenhagen | Denmark
1979 PIC Basic Standards of GMP - Need for Revision? Helsinki | Finland
1978 Large Volume Parenterals Oslo | Norway
1978 Good Manufacturing Practice in Tablet Manufacture Sunnindale | United Kingdom
1977 Modern Methodology for the Isolation, Identification and Quantification of Drugs and Related Substances Uppsala | Sweden
1976 Stability of Pharmaceutical Products Salzburg | Austria
1975 The Manufacturer's Quality Control Department Structural and Functional Aspects Copenhagen | Denmark
1974 Manufacture and Quality Control under Contract Berne | Switzerland
1973 Sampling and Analytical Control Edinburgh | United Kingdom
1972 The Quality of Pharmaceutical Products Rennes | France
1972 Contamination in the Manufacture of Pharmaceutical Products Stockholm | Sweden
1971 Safety Aspects Involved in the Packaging and Labelling of Pharmaceutical Products Geneva | Switzerland

Training Materials

All Seminar training materials are available under Materials. Login is required.

During the COVID-19 crisis, the PIC/S Secretariat remains open. If you need to reach us please contact us by e-mail only at the following e-mail address:

Thanks for your attention.